We reported recently that the posterior pituitary hormone oxytocin (OT) thought primarily to regulate lactation and social bonding is anabolic to the skeleton. Heterozygote mice with circulating OT reduced to half that of wild type mice showed no lactation defect, but instead displayed severe osteopenia and reduced bone formation. Bone resorption remained unaffected, likely due to the opposing actions of OT on osteoclast formation and function. Together the data suggest that the bone forming action of OT is dominant, and perhaps more ancient than its effect on the breast. Expectedly, OT injected into wild type mice increased bone mass by enhancing osteoblastogenesis, whereas in stromal cell cultures, it stimulated mineralized colony formation. Furthermore, we found recently that bone marrow osteoblasts not only possess abundant OT receptors (Oxtrs), but also produce OT. This means that an autocrine OT circuit in marrow could potentially amplify the bone forming action of injected OT. We hypothesize that OT is an anabolic bone hormone, and that its action is mediated through an osteoblast Oxtr, which when stimulated by OT, produces OT locally in an autocrine loop.
In Specific Aim 1, we will investigate whether injected OT can restore the lost bone in aging and hypogonadal mice.
In Specific Aim 2, we will elucidate, through cell-selective genetic ablation of the Oxtr, whether osteoblasts, osteoclasts or both cells participate in the action of OT.
In Specific Aim 3, we will determine whether marrow OT is required for the bone forming action of injected OT using OT-/- mice and bone marrow transplantation. Our studies should help establish OT and Oxtrs as potential targets for treating human osteoporosis.
Osteoporosis affects at least 50 million Americans who suffer from around 2.4 million debilitating fractures each year resulting in an overall expense of ~$18 billion. The present proposal underpins our more recent finding that a pituitary hormone, oxytocin (OT), regulates skeletal integrity. We will utilize a complement of pharmacological and mouse genetic studies to determine whether OT or its receptor can be leveraged to treat osteoporosis.
|Pazianas, Michael; Kim, Se-min; Yuen, Tony et al. (2015) Questioning the association between bisphosphonates and atypical femoral fractures. Ann N Y Acad Sci 1335:9-Jan|
|Colaianni, Graziana; Sun, Li; Zaidi, Mone et al. (2014) Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol 307:R970-7|
|New, Maria I; Tong, Yu K; Yuen, Tony et al. (2014) Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab 99:E1022-30|
|Mistry, Pramod K; Liu, Jun; Sun, Li et al. (2014) Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A 111:4934-9|
|Colaianni, G; Tamma, R; Di Benedetto, A et al. (2014) The oxytocin-bone axis. J Neuroendocrinol 26:53-7|
|Iqbal, Jameel; Sun, Li; Cao, Jay et al. (2013) Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci U S A 110:11115-20|
|Arnason, Barry G; Berkovich, Regina; Catania, Anna et al. (2013) Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 19:130-6|
|Sun, Li; Zhu, Ling-Ling; Lu, Ping et al. (2013) Genetic confirmation for a central role for TNF* in the direct action of thyroid stimulating hormone on the skeleton. Proc Natl Acad Sci U S A 110:9891-6|
|Haider, Shozeb; Islam, Barira; D'Atri, Valentina et al. (2013) Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia. Proc Natl Acad Sci U S A 110:2605-10|
|Tamma, Roberto; Sun, Li; Cuscito, Concetta et al. (2013) Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A 110:18644-9|
Showing the most recent 10 out of 14 publications